Navigation Links
Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
Date:5/13/2009

ties and the commercialization of all gastrin-based therapeutic products worldwide.

In August 2008, Transition and its collaboration partner Lilly initiated a Phase II trial evaluating TT-223 in type 2 diabetes patients receiving metformin and/or thiazolidinediones (TZDs) which completed enrolling patients in February 2009.

On March 23, 2009, Transition announced the initiation of a Phase Ib clinical study of TT-223 in combination with a GLP-1 analogue in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of GLP-1 analogue, for a combination treatment period of 4 weeks with a 5-month follow-up.

Juvenile Diabetes Research Foundation ("JDRF")

In September 2006, the Company entered into an agreement with the JDRF to support the clinical development of TT-223 in combination with GLP1 analogues for the treatment of type 1 diabetes over a two year period.

The original objective of the JDRF funding was to support efforts towards the development of an effective gastrin-based therapy for diabetes. The research funding used to date has supported meaningful work that has advanced the TT-223 combination therapies into position to begin clinical studies. Lilly will be fully supporting this clinical development work not only through financial resources, but through their expertise and specialized clinical development groups. With this in mind, Transition and the JDRF agreed that it would be reasonable for the JDRF to reassign financial resources earmarked for development of gastrin-based therapies to another worthy research program.

Accordingly, on April 3, 2009, the Company terminated the agreement with the JDRF and paid $441,455 (US$350,000) which represents the total amounts owing to the JDRF under the terms of the agre
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
2. TouchPointCare Introduces TPC Transition Home to Help Hospitals Reduce Unplanned Readmissions
3. Transition From Home to Hospital Rarely Seamless
4. iMedica Launches Transition™, a New, Streamlined EHR That Breaks Down the Barriers to Physician Adoption and Use
5. HCSC Discusses the Controversial ICD-10 Transition at the 2009 HIMSS Conference
6. The Quantum Group Announces Transition to Continental Stock Transfer
7. iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice
8. iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice
9. Northeastern Hospital to Transition to Northeastern Ambulatory Care Center
10. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
11. Mylan Announces Transition of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 The team at Advanced ... NJ, is proud to announce that they are ... PMR proudly offers many services, including Physical Therapy, ... medical supplies. Some of their physical therapy services ... geriatric therapy among a vast list of others. ...
(Date:7/31/2014)... In a front-page story, the Wall ... & Johnson, is withdrawing its laparoscopic power morcellator due ... This important story has also been reported by ... AP (7/30), the Pittsburgh Business Times (7/30) and TIME ... uterine procedures to, “slice up common uterine masses called ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... The Never Give Up 26 Foundation looks forward to seeing ... Simply bring your ticket and Mention Never Give Up 26 ... and family. , Packy had unique internal drives, ... optimism continues to impact the lives of many. Overcoming ... a happy life was truly a testament to his character. ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs' Approved, Advanced Physical Medicine and Rehabilitation Now Offering Chiropractic & Podiatric Services 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4
... that has been commissioned by the Australian government states that ... cost effective option to control// the growing epidemic of childhood ... found the various programs based in schools were cost-effective, but ... that many ministers for state who are in favour of ...
... Canada can differ according to provinces, says a new study ... ,People on dialysis in Alberta were four times more ... the study conducted over a five-year period found. Saskatchewan, Atlantic ... for kidneys than Ontario. ,"We can say that ...
... The National Institute of Virology in Pune declared Tuesday there ... 250 km from here in south Gujarat.// ,Additional ... samples from Surat city, and not even a single sample ... NIV, have not yet clarified why two persons had died ...
... August 26 issue of "The Lancet" has revealed that ... past decade// in many countries of the world, especially ... University of Auckland, New Zealand, and colleagues repeated the ... between 2002-2003 to assess the global prevalence of asthma, ...
... a Christchurch General Practitioner for allegedly manipulating a sexual ... account, the GP even bought her lingerie and advised ... ,The doctor has been slapped with a charge ... with the woman in question. Allegedly, the former ...
... Board has indicated that the Klein Government is all set ... early stage breast cancer.// The spokeswoman of the board, Lee ... trials in the United Kingdom before advising the $40,000-per-patient drug ... is available to those patients who are in dire need ...
Cached Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2Health News:Rise In Childhood Allergies 2
(Date:7/31/2014)... 31, 2014 Lazarus Effect, a medical device ... to facilitate removal of blood clots, announced the closing ... will support EU commercialization of several approved Lazarus Effect ... ReCover™ and Lazarus Cover™ in the United ... confidence in the value of our novel, platform technology ...
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... ... research and biotechnology companies are testing 97 medicines and vaccines to ... report released today by the Pharmaceutical Research and Manufacturers of America ... - a global awareness campaign that originated at the 1988 World ...
... , XI,AN, China, Nov. ... a leading developer and producer,of plant extracts and pharmaceutical raw ... China, today reported that in its,third quarter, the company realized ... Revenues for the quarter ended Sept. 30, 2009 were $4,465,770, ...
Cached Medicine Technology:New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4
7 mm curved blade. Round handle....
7 mm strong curved blade. Round handle....
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
No. 4. 0.75 mm wide x 5 mm long, lightly curved tip, offset to the left. Hexagonal handle....
Medicine Products: